{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:22:19Z","timestamp":1788535339755,"version":"build-2803163510"},"reference-count":96,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Aging"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the leading cause of dementia and represents a public health challenge in aging populations. Acetylcholinesterase inhibitors (AChEIs) remain first-line symptomatic therapy for mild to moderate AD, with real-world effectiveness largely influenced by tolerability, adherence, and treatment persistence. Galantamine and its inactive prodrug benzgalantamine are differentiated within the class by a dual mechanism that combines reversible acetylcholinesterase inhibition with positive allosteric modulation of nicotinic acetylcholine receptors. This narrative review synthesizes preclinical and clinical evidence examining galantamine-based therapy, with a focus on aspects related to nicotinic acetylcholine receptors: behavioral symptoms and sleep-related effects. Across randomized, observational, and longitudinal studies, galantamine has been associated with improvement or stabilization in behavioral domains including aberrant motor behavior, agitation\/aggression, anxiety, apathy, delusions, disinhibition, and hallucinations. However, like other members of the AChEI class, gastrointestinal tolerability issues may affect treatment persistence. Benzgalantamine was developed to address gastrointestinal tolerability, with the aim of improving adherence and long-term treatment continuity.<\/jats:p>","DOI":"10.1177\/30495334261485634","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:08:21Z","timestamp":1788293301000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Nicotinic Acetylcholine Receptor Modulation Distinguishes Clinical Benefits of Galantamine in Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4568-7842","authenticated-orcid":false,"given":"Pavel V.","family":"Svintozelskiy","sequence":"first","affiliation":[{"name":"Medical Affairs, Alpha Cognition, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wahlert","sequence":"additional","affiliation":[{"name":"Medical Affairs, Alpha Cognition, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-5286","authenticated-orcid":false,"given":"Carson","family":"Harrod","sequence":"additional","affiliation":[{"name":"Medical Affairs, Alpha Cognition, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis G.","family":"Kay","sequence":"additional","affiliation":[{"name":"Medical Affairs, Alpha Cognition, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt P.","family":"Grady","sequence":"additional","affiliation":[{"name":"Medical Affairs, Alpha Cognition, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George T.","family":"Grossberg","sequence":"additional","affiliation":[{"name":"St. Louis University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S2652"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.n222761"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.11R01CR"},{"issue":"1","key":"e_1_3_3_5_1","first-page":"105","article-title":"Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer\u2019s disease","volume":"2","author":"Allegri R. F.","year":"2006","unstructured":"Allegri R. F., Sarasola D., Serrano C. M., Taragano F. E., Arizaga R. L., Butman J., Lo\u00f1 L. (2006). Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer\u2019s disease. Neuropsychiatric Disease and Treatment, 2(1), 105\u2013110. https:\/\/doi.org\/10.2147\/ndt.s12160165","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"e_1_3_3_6_1","volume-title":"ZUNVEYL (benzgalantamine)","author":"Alpha Cognition, Inc","year":"2024","unstructured":"Alpha Cognition, Inc. (2024). ZUNVEYL (benzgalantamine). [Prescribing information]."},{"issue":"4","key":"e_1_3_3_7_1","article-title":"Alzheimer\u2019s disease facts and figures","volume":"22","author":"Alzheimer\u2019s Association","year":"2026","unstructured":"Alzheimer\u2019s Association. (2026). Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s & Dementia: The Journal of the Alzheimer\u2019s Association, 22(4). Article e71345. https:\/\/doi.org\/10.1002\/alz.71345","journal-title":"Alzheimer\u2019s & Dementia: The Journal of the Alzheimer\u2019s Association"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1946"},{"key":"e_1_3_3_9_1","first-page":"3","volume-title":"Nicotine in psychiatry: Psychopathology and emerging therapeutics","author":"Arneric S. P.","year":"2000","unstructured":"Arneric S. P. (2000). Neurobiology and clinical pathophysiology of neuronal nicotinic acetylcholine receptors. In Piasecki M., Newhouse P. A. (Eds.), Nicotine in psychiatry: Psychopathology and emerging therapeutics (pp. 3\u201335). American Psychiatric Press."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.08.047"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-017-0067-7"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2020_141"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001190.pub3"},{"issue":"9","key":"e_1_3_3_14_1","first-page":"CD001191","article-title":"Rivastigmine for Alzheimer\u2019s disease","volume":"2015","author":"Birks J. S.","year":"2015","unstructured":"Birks J. S., Chong L.-Y., Grimley Evans J. (2015). Rivastigmine for Alzheimer\u2019s disease. Cochrane Database of Systematic Reviews, 2015(9), CD001191. https:\/\/doi.org\/10.1002\/14651858.CD001191.pub4","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-023-01065-x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051229"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X20982383"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245789"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14827"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.09.011"},{"issue":"9","key":"e_1_3_3_21_1","first-page":"1343","article-title":"The effect of galantamine on sleep quality in Thai Alzheimer\u2019s disease patients","volume":"91","author":"Chankrachang S.","year":"2008","unstructured":"Chankrachang S., Praditsuwan S. (2008). The effect of galantamine on sleep quality in Thai Alzheimer\u2019s disease patients. Journal of the Medical Association of Thailand, 91(9), 1343\u20131349.","journal-title":"Journal of the Medical Association of Thailand"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-199821001-00009"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924000427"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.3.532"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.64.5.1217"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)01011-8"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-122140"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180583"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52529_3.x"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2141"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X13666150716165726"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-017-0438-x"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.2.137"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52303.x"},{"issue":"22","key":"e_1_3_3_36_1","first-page":"22","article-title":"Revisiting the role of acetylcholinesterase in Alzheimer\u2019s disease: Cross-talk with P-tau and \u03b2-amyloid","volume":"4","author":"Garc\u00eda-Ayll\u00f3n M.","year":"2011","unstructured":"Garc\u00eda-Ayll\u00f3n M., Small D., Avila J., S\u00e1ez-Valero J. (2011). Revisiting the role of acetylcholinesterase in Alzheimer\u2019s disease: Cross-talk with P-tau and \u03b2-amyloid. Frontiers in Molecular Neuroscience, 4(22), 22. https:\/\/doi.org\/10.3389\/fnmol.2011.00022","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2013.1268"},{"issue":"7","key":"e_1_3_3_38_1","first-page":"8S","article-title":"Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer\u2019s disease","volume":"46","author":"Geerts H.","year":"2006","unstructured":"Geerts H., Grossberg G. (2006). Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer\u2019s disease. The Journal of Clinical Pharmacology, 46(7 Suppl 1), 8S\u201316S. https:\/\/doi.org\/10.1177\/0091270006288734","journal-title":"The Journal of Clinical Pharmacology"},{"key":"e_1_3_3_39_1","first-page":"263","volume-title":"Alzheimer disease","author":"Geula C.","year":"1994","unstructured":"Geula C., Mesulam M.-M. (1994). Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In Terry R. D., Katzman R., Bick K. L. (Eds.), Alzheimer disease (pp. 263\u2013291). Raven Press."},{"key":"e_1_3_3_40_1","first-page":"391","article-title":"Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer\u2019s disease","volume":"10","author":"Hager K.","year":"2014","unstructured":"Hager K., Baseman A., Nye J. S., Brashear H. R., Han J., Sano M., Davis B., Richards H. M. (2014). Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer\u2019s disease. Neuropsychiatric Disease and Treatment, 10, 391\u2013401. https:\/\/doi.org\/10.2147\/NDT.S57909","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01481-0"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200926050-00004"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200506000-00012"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003748"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1995.tb07401.x"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1996.tb02942.x"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2007.02.020"},{"key":"e_1_3_3_49_1","first-page":"141","volume-title":"Neuronal nicotinic receptors: Pharmacology and therapeutic opportunities","author":"Kaiser S.","year":"1998","unstructured":"Kaiser S., Wonnacott S. (1998). Nicotinic receptor modulation of neurotransmitter release. In Arneric S. P., Brioni J. D. (Eds.), Neuronal nicotinic receptors: Pharmacology and therapeutic opportunities (pp. 141\u2013149). Wiley-Liss."},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph181910448"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900023178"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-101290"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2017.48"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145705005833"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1159\/000066508"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00472"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20542"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2002.tb00221.x"},{"issue":"11","key":"e_1_3_3_59_1","first-page":"CD001747","article-title":"Galantamine for dementia due to Alzheimer\u2019s disease and mild cognitive impairment","volume":"2024","author":"Lim A. W. Y.","year":"2024","unstructured":"Lim A. W. Y., Schneider L., Loy C. (2024). Galantamine for dementia due to Alzheimer\u2019s disease and mild cognitive impairment. Cochrane Database of Systematic Reviews, 2024(11), CD001747. https:\/\/doi.org\/10.1002\/14651858.CD001747.pub4","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53313.x"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.158964"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.3.310"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105031"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/26.5.602"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.2217\/nmt.12.55"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1197623"},{"issue":"3","key":"e_1_3_3_67_1","first-page":"89","article-title":"Alzheimer\u2019s disease: A brief review","volume":"1","author":"McGirr S.","year":"2020","unstructured":"McGirr S., Venegas C., Swaminathan A. (2020). Alzheimer\u2019s disease: A brief review. Journal of Experimental Neurology, 1(3), 89\u201398. https:\/\/doi.org\/10.33696\/Neurol.1.015","journal-title":"Journal of Experimental Neurology"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/728983"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-221125"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-015-0453-9"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150308"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0297-y"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1240514"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8739"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht182"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12132"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2018.04.005"},{"issue":"2","key":"e_1_3_3_78_1","first-page":"CD009081","article-title":"Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia","volume":"2021","author":"Parsons C.","year":"2021","unstructured":"Parsons C., Lim W. Y., Loy C., McGuinness B., Passmore P., Ward S. A., Hughes C. (2021). Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database of Systematic Reviews, 2021(2). Article CD009081. https:\/\/doi.org\/10.1002\/14651858.CD009081.pub2","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.nrl.0000087722.46430.c4"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.12.2261"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-021-00851-9"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt7"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S323387"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.045773"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2000.00310.x"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1159\/000362871"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.063586"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125003214"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.06.008"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.12.2269"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00051"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.12.1987"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7274.1445"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1301"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011832"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.16.2090"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115797"}],"container-title":["Sage Open Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/30495334261485634","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/30495334261485634","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/30495334261485634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:49:56Z","timestamp":1788533396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/30495334261485634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":96,"alternative-id":["10.1177\/30495334261485634"],"URL":"https:\/\/doi.org\/10.1177\/30495334261485634","relation":{},"ISSN":["3049-5334","3049-5334"],"issn-type":[{"value":"3049-5334","type":"print"},{"value":"3049-5334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"30495334261485634"}}